• DaVita Inc. recently reported first-quarter 2026 results, with revenue of US$3,415.55 million and net income of US$197.53 million, and also disclosed substantial progress on long-running share repurchase programs totaling several billions of dollars since 2020.
• The combination of stronger earnings, higher per-share profitability and an aggressively shrinking share count is reshaping how investors view DaVita’s long‑term financial profile.
• We’ll now examine how DaVita’s stronger first-quarter earnings and continued buybacks may influence the company’s existing investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

DaVita Investment Narrative Recap

To own DaVita, you need to believe its core dialysis business can generate steady cash flow while Integrated Kidney Care and clinical initiatives gradually support better margins. Right now, the key near term catalyst is operational execution translating into earnings per share, with the biggest risk coming from pressure on treatment volumes and reimbursement. The latest first quarter beat and ongoing buybacks support the EPS story, but do not remove these underlying volume and policy risks.

The most relevant recent development is DaVita’s update on its aggressive buyback activity, with over US$5,691.08 million spent under the 2020 plan and US$2,245.01 million under the 2024 plan. Combined with stronger first quarter earnings, this shrinking share count amplifies per share results and reinforces the near term earnings catalyst, even as concerns about GLP 1 impacts, insider selling and only moderate operating performance continue to sit in the background.

Yet behind the strong recent share price run, investors should still be aware of the elevated missed treatment rates and lingering volume pressures...

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029.

Uncover how DaVita's forecasts yield a $193.71 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about US$15.3 billion of revenue and US$803.0 million of earnings by 2029, which shows just how cautious views on DaVita’s volume and margin risks can be, especially around pressure on treatment volumes and payer mix, and why the latest first quarter surprise could eventually shift both the optimistic and pessimistic narratives you compare for yourself.

Explore 2 other fair value estimates on DaVita - why the stock might be worth 29% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

No Opportunity In DaVita?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.